galectin 3 levels (Galectin Therapeutics)
86
Structured Review
Galectin Therapeutics
galectin 3 levels
Galectin 3 Levels, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galectin-3/pm42316000-102-10-10
Average 86 stars, based on 1 article reviews
Galectin 3 Levels, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galectin-3/pm42316000-102-10-10
Average 86 stars, based on 1 article reviews
galectin 3 levels - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Biomarker Discovery:Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: Through these time-dependent changes in Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: • 14% of patients with primary Article Title: New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine Article Snippet: Mechanistically , SHP-1 dampens TCR signaling by dephosphorylating pivotal kinases, thereby suppressing T-cell proliferation [ ], while CD39 hydrolyzes extracellular ATP/ADP to adenosine, impairing T-cell metabolism [ ]. ( .b) Cytokines including IL-2, IL-4, and IL-7 significantly enhance Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: In our study, we investigated several hemostatic biomarkers at baseline and during follow-up, of which higher vWF activity ( , upper panel), Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: The Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: Whether lower levels of Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: In addition to prior history of VTE, as discussed above, we found in an exploratory analysis of all VTE events that higher Standard Deviation:Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: Through these time-dependent changes in Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: • 14% of patients with primary Article Title: New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine Article Snippet: Mechanistically , SHP-1 dampens TCR signaling by dephosphorylating pivotal kinases, thereby suppressing T-cell proliferation [ ], while CD39 hydrolyzes extracellular ATP/ADP to adenosine, impairing T-cell metabolism [ ]. ( .b) Cytokines including IL-2, IL-4, and IL-7 significantly enhance Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: In our study, we investigated several hemostatic biomarkers at baseline and during follow-up, of which higher vWF activity ( , upper panel), Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: The Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: Whether lower levels of Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: In addition to prior history of VTE, as discussed above, we found in an exploratory analysis of all VTE events that higher Activity Assay:Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: Through these time-dependent changes in Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: • 14% of patients with primary Article Title: New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine Article Snippet: Mechanistically , SHP-1 dampens TCR signaling by dephosphorylating pivotal kinases, thereby suppressing T-cell proliferation [ ], while CD39 hydrolyzes extracellular ATP/ADP to adenosine, impairing T-cell metabolism [ ]. ( .b) Cytokines including IL-2, IL-4, and IL-7 significantly enhance Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: In our study, we investigated several hemostatic biomarkers at baseline and during follow-up, of which higher vWF activity ( , upper panel), Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: The Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: Whether lower levels of Article Title: Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors Article Snippet: In addition to prior history of VTE, as discussed above, we found in an exploratory analysis of all VTE events that higher |